IN2014MN02554A - - Google Patents

Info

Publication number
IN2014MN02554A
IN2014MN02554A IN2554MUN2014A IN2014MN02554A IN 2014MN02554 A IN2014MN02554 A IN 2014MN02554A IN 2554MUN2014 A IN2554MUN2014 A IN 2554MUN2014A IN 2014MN02554 A IN2014MN02554 A IN 2014MN02554A
Authority
IN
India
Prior art keywords
inhibitors
relates
protein kinase
present
tec
Prior art date
Application number
Other languages
English (en)
Inventor
Alain Laurent
Yannick Rose
Original Assignee
Pharmascience Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmascience Inc filed Critical Pharmascience Inc
Publication of IN2014MN02554A publication Critical patent/IN2014MN02554A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IN2554MUN2014 2012-07-06 2013-07-03 IN2014MN02554A (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CA2782774A CA2782774A1 (en) 2012-07-06 2012-07-06 Protein kinase inhibitors
PCT/CA2013/000612 WO2014005217A1 (en) 2012-07-06 2013-07-03 Protein kinase inhibitors

Publications (1)

Publication Number Publication Date
IN2014MN02554A true IN2014MN02554A (pl) 2015-07-24

Family

ID=49881186

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2554MUN2014 IN2014MN02554A (pl) 2012-07-06 2013-07-03

Country Status (12)

Country Link
US (2) US9447102B2 (pl)
EP (1) EP2870158B1 (pl)
JP (1) JP6190881B2 (pl)
KR (2) KR20180107328A (pl)
CN (1) CN104718207B (pl)
BR (1) BR112014033056A2 (pl)
CA (2) CA2782774A1 (pl)
ES (1) ES2631228T3 (pl)
HK (1) HK1209726A1 (pl)
IN (1) IN2014MN02554A (pl)
RU (1) RU2679122C2 (pl)
WO (1) WO2014005217A1 (pl)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2782774A1 (en) * 2012-07-06 2014-01-06 Pharmascience Inc. Protein kinase inhibitors
CA2833701A1 (en) * 2013-11-19 2015-05-19 Pharmascience Inc. Protein kinase inhibitors
CA2833867A1 (en) * 2013-11-21 2015-05-21 Pharmascience Inc. Protein kinase inhibitors
CA2834528A1 (en) * 2013-11-26 2015-05-26 Pharmascience Inc. Protein kinase inhibitors
CN103787839B (zh) * 2014-01-21 2015-12-02 苏州昊帆生物科技有限公司 合成2,3,4,5,6-五氟苯酚的方法
EP3337805A4 (en) * 2015-05-27 2019-04-03 Pharmascience Inc. INHIBITORS OF THE TEC KINASE ENZYM FAMILY
CN114685516A (zh) * 2015-09-16 2022-07-01 洛克索肿瘤学股份有限公司 用于治疗癌症的作为btk抑制剂的吡唑并嘧啶衍生物
WO2017134685A2 (en) * 2016-02-02 2017-08-10 Sun Pharma Advanced Research Company Limited Novel hydrazino compounds as btk inhibitors
EP3492471B1 (en) * 2016-08-17 2020-12-02 Shenzhen TargetRx, Inc. Fused bicyclic compound for inhibiting activity of tyrosine kinase
EP3942045A1 (en) 2019-03-21 2022-01-26 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
EP4054579A1 (en) 2019-11-08 2022-09-14 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
MX2023002691A (es) * 2020-09-03 2023-05-03 Amgen Inc Desimetrización de diol mediante sustitución aromática nucleófila.

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3736728A1 (de) * 1987-10-29 1989-05-11 Siemens Ag Druckertinte
DE59310344D1 (de) * 1992-09-24 2003-07-24 Hoechst Ag N1-Substituierte 1H-1,2,3-Triazolo[4,5-d]pyrimidine, Verfahren zu ihrer Herstellung sowie ihre Verwendung als antivirale Mittel
WO2001019828A2 (en) * 1999-09-17 2001-03-22 Basf Aktiengesellschaft Kinase inhibitors as therapeutic agents
DE10031584A1 (de) * 2000-06-29 2002-01-10 Merck Patent Gmbh 5-Aminoalkyl-pyrazolo[4,3-d]pyrimidine
US20030199525A1 (en) * 2002-03-21 2003-10-23 Hirst Gavin C. Kinase inhibitors
SG10201508035TA (en) * 2007-03-28 2015-10-29 Pharmacyclics Inc Inhibitors of bruton's tyrosine kinase
CA2782774A1 (en) * 2012-07-06 2014-01-06 Pharmascience Inc. Protein kinase inhibitors
KR102229478B1 (ko) * 2012-11-01 2021-03-18 인피니티 파마슈티칼스, 인코포레이티드 Pi3 키나아제 동형단백질 조절인자를 사용하는 암의 치료

Also Published As

Publication number Publication date
RU2679122C2 (ru) 2019-02-06
US9795608B2 (en) 2017-10-24
EP2870158A1 (en) 2015-05-13
KR20150041784A (ko) 2015-04-17
WO2014005217A1 (en) 2014-01-09
KR20180107328A (ko) 2018-10-01
US9447102B2 (en) 2016-09-20
BR112014033056A2 (pt) 2017-06-27
EP2870158A4 (en) 2015-12-09
CA2878332C (en) 2019-04-30
EP2870158B1 (en) 2017-05-31
HK1209726A1 (en) 2016-04-08
CA2782774A1 (en) 2014-01-06
CA2878332A1 (en) 2014-01-09
US20150344478A1 (en) 2015-12-03
JP6190881B2 (ja) 2017-08-30
JP2015521987A (ja) 2015-08-03
CN104718207B (zh) 2017-08-15
RU2014151421A (ru) 2016-08-27
CN104718207A (zh) 2015-06-17
US20160375027A1 (en) 2016-12-29
ES2631228T3 (es) 2017-08-29
KR101903123B1 (ko) 2018-10-01

Similar Documents

Publication Publication Date Title
HK1209726A1 (en) Protein kinase inhibitors
EA201400833A1 (ru) Новые индолизиновые соединения, способ их получения и фармацевтические композиции, содержащие их
TN2014000138A1 (en) Substituted benzylindazoles for use as bub1 kinase inhibitors in the treatment of hyperproliferative diseases.
UA116648C2 (uk) Фумарати як проліки та їх застосування при лікуванні різних захворювань
PH12014000179A1 (en) New pyrrole compounds, a process for their preparation and pharmaceutical compositions containing them
MX378194B (es) Compuestos organicos.
GEAP202413811A (en) Processes for preparing quinoline compounds and pharmaceutical compositions containing such compounds
PH12015501385A1 (en) Autotaxin inhibitors
MX357305B (es) Compuestos y composiciones para inhibir la actividad de abl-1, abl-2, y bcr-abl1.
TN2014000516A1 (en) New thienopyrimidine derivatives, a process for their preparation and pharmaceutical compositions containing them
PH12016500094A1 (en) Autotaxin inhibitors
PH12016500057A1 (en) Novel indolizine compounds, a process for their preparation and pharmaceutical compositions containing them
IN2014MN02598A (pl)
MX353806B (es) Quinolinas como moduladores de cinasas del receptor del factor de crecimiento de fibroblasto (fgfr).
TN2014000427A1 (en) Benzamide derivatives for inhibiting the activity of abl1, abl2 and bcr-abl1
PH12013501922A1 (en) Protein kinase inhibitors
EA201590161A1 (ru) Составы этанерцепта, отличающиеся заметным уменьшением содержания частиц довидимого диапазона
PH12014501514A1 (en) New azetidine derivatives, pharmaceutical compositions and uses thereof
TN2013000400A1 (en) Imidazopyridazines as akt kinase inhibitors
MX353847B (es) Composicion farmaceutica de rosuvastatina calcica.
MX2016000900A (es) Nuevos derivados de indol y de pirrol, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
IN2014MN02338A (pl)
GEP20207108B (en) Substituted 2,4 diamino-quinoline as new anticancer agents
MX2014006433A (es) Nuevos 2h-indazoles como antagonistas del receptor ep2.
PH12015501175A1 (en) Substituted pyridopyrazines as syk inhibitors